June 15th, 2022

NEUREVO received FDA approval for accelerated orphan drug development (ODD) for treatment of amyotrophic lateral sclerosis (ALS). Click here to read the press release

December 14th, 2021

Fresh from the press: Study on the use of our lead candidate to treat stroke is out!

November 15th, 2021

Neurevo´s treatment for ALS obtains the Orphan Drug Designation from the European Commission!

October 14th, 2021

NEUREVO´s treatment for ALS obtains a positive opinion from the Committee for Orphan Medicinal Products (COMP)

October 13th, 2021

European Patent Office grants patent for the use of glycolic acid as a treatment for ischemia!

June 28th, 2021

NEUREVO selected as one of the winners of the Science4Life Venture Cup 2021!!!


May 27th, 2021

NEUREVO has been considered by the BAFA as eligible for the INVEST funding program of the German Federal Ministry for Economic Affairs and Energy. INVEST provides grants for venture capital from private investors or small companies (max. 10 shareholders) investing in young innovative companies. Investors get 20% of their investment with a minimun investment size of 10.000€ and a maximum of 500.000€ per person.

May 11th, 2021

NEUREVO participated as one of the selected Start-ups from Germany, Austria and Switzerland in the EITH Catapult Regional Competition 2021!!

February 10th, 2021

NEUREVO´s solution for stroke featured in STROKE´s editorial as a promising neuroprotective therapy!

January 27th, 2021

NEUREVO GmbH has been selected as one of the Top 50 Start-ups in Germany!

January 17th, 2021

Preprint of our paper on the positive effect of glycolic acid on sperm motility, mitosis, embryonic development and energy production is available online at BioRxiv!

January, 2021

Meet us at the LSX WORLD Congress! NEUREVO is attending the LSX WORLD Congress taking place February 1-5th, 2021 (virtual event). We will have the opportunity to do partnering meetings to get to know each other and to provide you with more information about Neurevo´s product development on neurological diseases.

January, 2021

EXIST Phase II Grant obtained after foundation of NEUREVO GmbH

November 24th, 2020

Preprint of our paper on the protective effect of glycolic acid on ischemia available online at BioRxiv!

July 21st, 2020

NEUREVO wins Munich Business Plan Competition Phase 3!

May 12th, 2020

NEUREVO is under the top 10 of over 100 participants in the Munich Business Plan Competition Phase 2.

March 16th, 2020

NEUREVO was selected as one of the best participants of Phase 2 (Konzeptphase) of Science4Life Venture Cup and participated in the “Academy Days”.

March 3rd , 2020

NEUREVO reached the top 10 of 150 participants of phase 1 of the Munich business plan competition.

November 22th, 2019

NEUREVO was selected as one of the best participants of Phase 1 (Ideenphase) of Science4Life Venture Cup and participated in the “Academy Days” in Frankfurt

July 12th, 2019

NEUREVO (former project name “GLYMIPRO”) took part in the three-month «EIT Health BioEntrepreneurship Lab Oxford-Munich 2019» and validated their innovative biotech business concept:

July 11th, 2019

NEUREVO (former project name “GLYMIPRO”) presented their top-class research to 19 investors, four pharmaceutical companies, one family office and one industry partner on the “5th Munich Life Science Pitch Day” of the High-Tech Gründerfond (HTGF).